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Abstract
Background and Aims: Liver stiffness measurement (LSM) and FibroTest (FT) are frequently used as non-invasive
alternatives for fibrosis staging to liver biopsy. However, to date, diagnostic performances of Enhanced Liver Fibrosis (ELF)
test, which consists of hyaluronic acid, aminoterminal propeptide of procollagen type-III, and tissue inhibitor of matrix
metalloproteinases-1, have not been compared to those of LSM and FT in Asian chronic hepatitis B (CHB) patients.
Methods: Between June 2010 and November 2011, we prospectively enrolled 170 CHB patients who underwent liver
biopsies along with LSM, FT, and ELF. The Batts system was used to assess fibrosis stages.
Results: Areas under receiver operating characteristic curves (AUROCs) to predict significant fibrosis (F$2), advanced
fibrosis (F$3), and cirrhosis (F = 4) were 0.901, 0.860, and 0.862 for ELF, respectively; 0.937, 0.956, and 0.963 for LSM; and
0.896, 0.921, and 0.881 for FT. AUROCs to predict F$2 were similar between each other, whereas LSM and FT had better
AUROCs than ELF for predicting F$3 (both p,0.05), and LSM predicted F4 more accurately than ELF (p,0.05). Optimized
cutoffs of ELF to maximize sum of sensitivity and specificity were 8.5, 9.4, and 10.1 for F$2, F$3, and F = 4, respectively.
Using suggested ELF, LSM and FT cutoffs to diagnose F1, F2, F3, and F4, 91 (53.5%), 117 (68.8%), and 110 (64.7%) patients,
respectively, were correctly classified according to histological results.
Conclusions: ELF demonstrated considerable diagnostic value in fibrosis staging in Asian CHB patients, especially in
predicting F$2. However, LSM consistently provided better performance for predicting F$3 and F4.
Citation: Kim BK, Kim HS, Park JY, Kim DY, Ahn SH, et al. (2012) Prospective Validation of ELF Test in Comparison with Fibroscan and FibroTest to Predict Liver
Fibrosis in Asian Subjects with Chronic Hepatitis B. PLoS ONE 7(7): e41964. doi:10.1371/journal.pone.0041964
Editor: Pal Bela Szecsi, Lund University Hospital, Sweden
Received May 2, 2012; Accepted June 27, 2012; Published July 27, 2012
Copyright:  2012 Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This study was supported by the Liver Cirrhosis Clinical Research Center, in part by a grant from the Korea Healthcare technology R & D project,
Ministry of Health and Welfare, Republic of Korea (no. A102065), and by the Yonsei Liver Blood Bank (YLBB), in part by a grant from sanofi-aventis Korea.
BioPredictive kindly provided the complimentary service for calculation of FT score. The funders had no role in study design, data collection and analysis, decision
to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: ksukorea@yuhs.ac
Introduction
Accurate assessment of the severity of liver fibrosis in patients
with chronic hepatitis B (CHB) is necessary for not only prediction
of the long-term clinical course, but also determination of whether
and when to begin antiviral therapy. The most recent guidelines
on the management of CHB proposed that the presence of
significant fibrosis with detectable serum hepatitis B virus (HBV)
DNA indicates antiviral therapy, since viral suppression can
reduce liver-related complications in patients with CHB who have
significant fibrosis to cirrhosis [1,2]. Conversely, in patients
without significant fibrosis and low levels of circulating virus, it
is more appropriate to monitor rather than initiate expensive and
potentially long-lasting antiviral therapy [1]. Furthermore, since
patients with cirrhosis should be entered into the active
surveillance program for early detection of hepatocellular carci-
noma (HCC) and other complications associated with hepatic
decompensation, including gastroesophageal varices, assessment of
fibrosis in patients with CHB has become an important clinical
issue for physicians [3].
To-date, liver biopsy has been the gold standard to assess liver
fibrosis. It is often limited, however, by its invasiveness, cost, risk of
complications, poor acceptance by patients, lack of availability of
expert practitioners, and intra/inter-observer variability [4]. These
drawbacks have also made sequential liver biopsies unfeasible,
especially when repeated examinations are required to monitor the
response to antiviral or anti-fibrosis treatment. Consequently,
noninvasive approaches combining several biochemical parame-
ters have been introduced, including aspartate aminotransferase
(AST)-to-platelet ratio index (APRI) [5], AST-alanine aminotrans-
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ferase (ALT) ratio [6], Forns test [7], and FibroTest (FT;
BioPredictive, Paris, France) [8]. Among them, FT is a commer-
cially available, popular, and non-invasive surrogate, which had
been substantially validated in Caucasian patients with chronic
hepatitis C (CHC), and thereafter in Asian subjects with CHB
[9,10,11,12,13]. Meanwhile, liver stiffness measurement (LSM)
using transient elastography (TE; FibroScanH; Echosens, Paris,
France), which calculates liver elasticity using a low frequency
elastic wave transmitted through the liver, has been introduced
recently and proven useful for non-invasive assessment of liver
fibrosis among subjects with chronic liver diseases (CLDs) due to
various etiologies [14,15,16].
In 2004, the Original European Liver Fibrosis panel of serum
markers of liver fibrosis incorporates hyaluronic acid (HA), tissue
inhibitor of matrix metalloproteinases-1 (TIMP-1), and amino-
terminal propeptide of procollagen type III (P3NP), all of which
are involved in the synthesis and degradation of the extracellular
matrix. It showed good diagnostic accuracy for the detection of
moderate and severe fibrosis in a cohort of patients with mixed
etiology CLDs, mainly due to hepatitis C virus (HCV) infection
(49%) [17]. Thereafter, it was simplified by removing age while
maintaining diagnostic accuracy, to establish the Enhanced Liver
Fibrosis Test (ELF, Siemens Diagnostics, NY, USA) [18]. This can
accurately predict significant liver fibrosis in independent popu-
lations [18,19,20,21]. However, in contrast to other non-invasive
surrogate markers available in the current clinical practice, few
studies have investigated the diagnostic performance of ELF test in
patients with CHB [22]. In particular, no previous study has
focused on Asian patients with CHB.
Here, the present study prospectively compared the diagnostic
value of ELF test in Asian populations with CHB with that of LSM
and FT, two well-known non-invasive alternatives to liver biopsy,
and defined optimized thresholds for prediction of liver fibrosis.
Materials and Methods
Patients’ eligibility
From the database of the liver cirrhosis clinical research center
at Severance Hospital, Yonsei University College of Medicine,
Seoul, Korea, consecutive patients with CHB who underwent liver
biopsy along with ELF test, LSM and FT on the same day
between June 2010 and November 2011, were selected for this
study. Liver biopsy was performed to assess the severity of fibrosis
and inflammation prior to antiviral therapy.
The exclusion criteria were: previous history of antiviral
therapy; the presence of HCC or history of it at the time of liver
biopsy; any malignancy other than HCC during the study period;
liver biopsy specimen smaller than 20 mm; co-infection with
human immunodeficiency virus or HCV; LSM failure or invalid
liver stiffness (LS) values with fewer than ten successful acquisi-
tions, a success rate of less than 60%, or interquartile range (IQR)/
median value ratio (IQR/M) greater than 0.3; alcohol ingestion in
excess of 40 g/day for more than 5 years; or right-sided heart
failure (Figure 1).
This study was performed in accordance with the ethical
guidelines of the 1975 Declaration of Helsinki. Written informed
consent was obtained from each participant or responsible family
member after possible complications of the diagnostic procedures
had been explained fully. This study was approved by the
institutional review board of Severance Hospital.
Liver biopsy examination
Percutaneous liver biopsy was performed using a 16-g
disposable needle immediately following LSM. The liver biopsy
specimens were fixed in formalin and embedded in paraffin. Then,
sections 4 mm thick were stained with hematoxylin and eosin
(H&E) and Masson’s trichrome. All liver tissue samples were
evaluated by an experienced hepatopathologist who was blinded
to the patients’ clinical histories. Specimens that were smaller than
20 mm or considered by the pathologists to be unsuitable for
fibrosis assessment were excluded from the analysis. Liver
histology was evaluated semi-quantitatively according to the Batts
and Ludwig scoring system [23]. Fibrosis was staged on a 0–4
scale: F0, no fibrosis; F1, portal fibrosis; F2, periportal fibrosis; F3,
septal fibrosis; and F4, cirrhosis. Significant fibrosis was defined as
F2 or more and advanced fibrosis as F3 or more.
ELF test
On the same day as LSM and liver biopsy, fasting blood
samples were obtained and the serum was stored at 280uC.
PIIINP, HA and TIMP-1 were measured using an ADVIA
Centaur XP automated immunoanalyzer (Siemens Healthcare
Diagnostics, Tarrytown, NY, USA). The ELF score was calculated
using the algorithm recommended in the CE-marked assay
[ELF=2.278+0.851 ln(HA)+0.751 ln(PIIINP)+0.394 ln(TIMP-1)].
FT score
On the same day as LSM and liver biopsy, the FT score
parameters, including a2-macroglobulin, apolipoprotein A1,
haptoglobin, c-GGT, and total bilirubin, were assessed. The FT
score was computed on the BioPredictive website (www.
biopredictive.com) as follows: f = 4.4676log[a2-macroglobulin
(g/L)]21.3576log[haptoglobin (g/L)]+1.0176log[c-GGT (IU/
L)]+0.02816[age (in years)]+1.7376log[bilirubin (mmol/
L)]21.1846[apolipoprotein A1 (g/L)]+0.3016sex (female = 0,
male = 1)25.540.
LSM
LSM was performed by one well-trained technician blinded to
patients’ clinical and laboratory data on the same day as liver
biopsy and the laboratory studies, including ELF test and FT.
Details of the technique and examination procedure have been
published previously [24,25]. The results were expressed in
kilopascals (kPa). IQR was defined as an index of intrinsic
variability of LS values corresponding to the interval of the LS
results containing 50% of the valid measurements between the
25th and 75th percentiles. The median value was considered
representative of the elastic modulus of the liver. Only procedures
with at least 10 valid measurements, a success rate of at least 60%,
and an IQR/M ,30% were considered reliable.
Statistical analyses
The major goals of this study were to prospectively validate the
diagnostic performance of ELF test to detect histologically
confirmed significant fibrosis, advanced fibrosis, and cirrhosis
and compared with that of LSM and FT, and to suggest optimal
cutoff values of ELF test for Asian patients with CHB. To assess
the diagnostic performance of each non-invasive index, receiver
operating characteristic (ROC) curves were constructed and the
areas under the ROC curves (AUROCs) were calculated. Then, to
evaluate the usefulness of the non-invasive method, the sensitivity,
specificity, positive predictive value (PPV), and negative predictive
value (NPV) were determined from the ROC curves. The Hanley
and McNeil test was used to compare the AUROC between two
non-invasive models [26]. The most discriminant cutoff values
were determined from the ROC curves to maximize the sum of
sensitivity and specificity [27].
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Statistical analyses were performed using SAS software, version
9.1.3 (SAS, Cary, NC). In all analyses, p,0.05 was considered
statistically significant.
Results
Patients’ baseline characteristics
A total of 253 consecutive patients were screened for possible
inclusion in the study. Based on the exclusion criteria, a total of
170 patients (mean age 45.3 years, 102 male) were included
(Figure 1).
The patients’ characteristics are summarized in Table 1. The
mean AST level was 45.9 IU/L, while the mean ALT level was
62.9 IU/L. The mean value of the ELF test was 9.5661.69, while
those of the LSM and FT were 12.2467.76 kPa and 0.5560.30,
respectively. The mean length and the median number of
fragments of liver biopsy samples were 21.3 mm and 2,
respectively. The fibrosis stages were F0 in 10 (5.9%) patients,
F1 in 39 (22.9%), F2 in 36 (21.2%), F3 in 38 (22.4%), and F4 in 47
(27.6%). All patients had adequate liver function.
Diagnostic performances of the ELF test in comparison
with LSM and FT
As shown in Figure 2, the overall mean values of ELF test
increased parallel to the stage of fibrosis (8.0160.84 in F0-1,
9.2460.77 in F2, 10.0361.54 in F3, and 11.1061.49 in F4, all
p,0.05 between adjacent fibrosis stages). The Spearman correla-
tion coefficient of ELF test with histological fibrosis stages was
0.724 (p,0.001). Similarly, the mean value of the LSM and FT
also significantly increased; 5.1361.54 kPa in F0-1,
7.4262.53 kPa in F2, 12.1863.00 kPa in F3, and
23.41611.66 kPa in F4 for LSM and 0.1660.08 in F0-1,
0.3060.16 in F2, 0.6160.23 in F3, and 0.7560.20 in F4 for FT
(all p,0.05 between adjacent fibrosis stages). The Spearman
correlation coefficient of LSM and FT with histological fibrosis
stages was 0.881 and 0.780, respectively (both p,0.001).
With regard to the diagnostic performances of ELF test for
prediction of liver fibrosis, the AUROC was 0.901 (95%
confidence interval [CI] 0.849–0.953) for significant fibrosis
(F$2) (Figure 3A), 0.860 (95% CI 0.805–0.915) for advanced
fibrosis (F$3) (Figure 3B), and 0.862 (0.809–0915) for cirrhosis
(F = 4) (Figure 3C) (Table 2). ROC curves and AUROCs of
LSM and FT are also shown (Figure 3 and Table 2). The
diagnostic performances of each component of ELF (HA, TIMP-1,
and P3NP) and FT (a2-macroglobulin, haptoglobin, c-GGT,
bilirubin, and apolipoprotein A1) for prediction of significant
fibrosis, advanced fibrosis, and cirrhosis are described in Table
S1. Overall, the coefficient of variations (CV= standard devia-
tion/mean) of ELF was 17.7%, while those of LSM and FT were
79.7% and 66.1%, respectively.
Among the three non-invasive methods, LSM consistently
showed the highest AUROC for prediction of significant fibrosis,
advanced fibrosis, and cirrhosis (Figure 4 and Table 2).
Although the accuracy of the three markers for prediction of
significant fibrosis was statistically equivalent (all p.0.05), LSM
showed significantly superior diagnostic efficacy over ELF test for
Figure 1. Flow chart describing the selection of the study population. Based on the exclusion criteria, 170 subjects were finally recruited for
analyses.
doi:10.1371/journal.pone.0041964.g001
Table 1. Baseline characteristics (n = 170).
Characteristics Value
Demographic data
Age (years) 45.3615.1
Male gender, no. (%) 102 (60.0)
Body mass index (kg/m2) 23.462.8
Laboratory data
Serum albumin (g/dL) 4.260.51
Total bilirubin (mg/dL) 1.2660.90
Aspartate aminotransferase (IU/L) 45.9621.3
Alanine aminotransferase (IU/L) 62.9626.1
Prothrombin time (%) 90.2613.9
Platelet count (109/L) 183.9673.3
Biopsy length (mm) 21.360.7
Enhanced liver fibrosis test 9.5661.69
Liver stiffness (kPa) 12.2467.76
FibroTest 0.5560.30
Fibrosis stage, no. (%)
F0 10 (5.9%)
F1 39 (22.9%)
F2 36 (21.2%)
F3 38 (22.4%)
F4 47 (27.6%)
Values were expressed as mean 6 standard deviation, unless indicated
otherwise.
doi:10.1371/journal.pone.0041964.t001
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predicting advanced fibrosis and cirrhosis (both p,0.001), and FT
had better AUROCs than ELF test for predicting advanced
fibrosis (F$3) (p = 0.038) (Figure 4 and Table 2).
Determination of the optimal cutoffs for the ELF test
The most discriminant cutoff values for ELF test are indicated
in Table 2. ELF cutoff values of 8.5, 9.40, and 10.10 generated a
sensitivity of 86.0%, specificity of 85.7%, PPV of 93.7% and NPV
of 71.2% for F$2; sensitivity of 83.5%, specificity of 77.7%, PPV
of 78.9%, and NPV of 82.5% for F$3; sensitivity of 70.2%,
specificity of 78.9%, PPV of 55.9%, and NPV of 87.4% for F= 4.
The corresponding cutoff values of LSM and FT for each
histological stage and their diagnostic indices are shown in detail in
Table 2.
Agreement between histological results and the ELF test,
LSM, or FT
ELF test agreed with liver histology for fibrosis levels of F,2 vs.
F$2 in 146 (85.8%) patients, which was higher than LSM
(n= 142, 83.5%) and FT (n= 138, 81.2%). However, the ELF
predicted the fibrosis stage less accurately (confirmed histological-
ly) for levels F,3 vs. F$3 (n= 135, 79.4%) and F4 (n= 126,
74.1%) than did LSM (n= 158, 92.9% and n= 150, 88.2%,
Figure 2. Box plots of ELF test according to fibrosis stage. Boxes and horizontal lines within boxes represent interquartile ranges (IQRs) and
median values, respectively. The upper and lower whiskers indicate 75th percentile plus 1.5 IQR and 25th percentile minus 1.5 IQR, respectively. o, mild
outlier: a value more than 75th percentile plus 1.5 IQR, but less than 75th percentile plus 3.0 IQR.
doi:10.1371/journal.pone.0041964.g002
Figure 3. Receiver operating characteristic (ROC) curves for ELF test, LSM and FT in the diagnosis of significant fibrosis ($F2, A),
advanced fibrosis ($F3, B), and cirrhosis (F =4, C).
doi:10.1371/journal.pone.0041964.g003
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respectively) or FT (n= 155, 91.2% and n= 141, 82.9%,
respectively) (Table 3).
In addition, when using the suggested cutoffs of ELF test, LSM,
and FT to diagnose each histological fibrosis stage (F1, F2, F3, and
F4), 91 (53.5%), 117 (68.8%), and 110 (64.7%) patients (gray-
colored area in Table 3) were correctly classified according to
histological results, meaning that liver biopsy could have been
replaced with these non-invasive methods (Table 3).
Discordance between histological results and ELF test
Discordant results between fibrosis stages estimated by liver
biopsy and ELF test were identified in 79 (46.5%) patients. On
multivariate analysis, only the presence of histological cirrhosis was
identified as a single significant factor, which was negatively
associated with discordance between liver biopsy and ELF test
(p,0.001; odds ratio 0.249, 95% CI 0.116–0.533), although, on
univariate analysis, the mean ALT level differed significantly
between patients with non-disconcordance and discordance (65
vs.76 IU/L, p=0.035), along with the proportion of subjects with
histological cirrhosis.
Discussion
Most studies that proposed ELF test as a good non-invasive
alternative to liver biopsy have focused primarily on populations
with HCV infection or nonalcoholic fatty liver disease [18,28] or
those with mixed etiologies including viral hepatitis, primary
biliary cirrhosis, etc. [19,22,29]. Since the diagnostic cutoffs of such
non-invasive indices based on biochemical parameters can vary,
even when the etiology is the same, possibly due to different
distribution of fibrosis stages and different baseline biochemical
profiles, a new study to generate standardized results in Asian
patients with CHB is warranted. To the best of our knowledge, this
is the first study to assess the diagnostic value of ELF test and to
define new cutoff values for each fibrosis stage optimized for a
homogenous Asian population with CHB.
Although the underlying mechanisms of fibrosis progression in
chronic viral hepatitis are expected to be similar, differences
Table 2. Diagnostic performances of LSM, FT and ELF and their suggested optimal cutoff values.
Fibrosis stage Method AUROC (95% CI) Cutoffs Sensitivity (%) Specificity (%) PPV (%) NPV (%)
ELF 0.901 (0.849–0.953) 8.50 86.0 85.7 93.7 71.2
F$2 LSM 0.937 (0.903–0.971) 8.0 kPa 77.7 95.9 97.9 63.5
FT 0.896 (0.850–0.942) 0.31 75.2 97.9 98.9 61.5
ELF 0.860 (0.805–0.915) 9.40 83.5 77.7 78.9 82.5
F$3 LSM* 0.956 (0.929–0.983) 10.1 kPa 90.6 96.5 96.2 91.1
FT* 0.921 (0.877–0.964) 0.51 85.8 97.7 97.3 87.4
ELF 0.862 (0.809–0915) 10.10 70.2 78.9 55.9 87.4
F=4 LSM* 0.963 (0.937–0.989) 14.0 kPa 87.2 91.1 78.8 94.9
FT 0.881 (0.828–0.935) 0.67 78.7 78.8 68.5 91.4
Abbreviations: ELF, enhanced liver fibrosis; LSM, liver stiffness measurement; FT, FibroTest; AUROC, area under the receiver operating characteristics curve; CI,
confidence interval; PPV, positive predictive value; NPV, negative predictive value.
*p,0.05 compared to AUROC of ELF using Hanley and McNeil test.
doi:10.1371/journal.pone.0041964.t002
Figure 4. Detailed AUROCs of ELF test, LSM and FT in the diagnosis of significant fibrosis ($F2), advanced fibrosis ($F3), and
cirrhosis (F =4).
doi:10.1371/journal.pone.0041964.g004
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according to etiology may affect the diagnostic accuracy of non-
invasive tests [30,31]. For example, patients with CHC often have
steatosis, which may influence baseline biochemical parameters,
and they also tend to have micronodular cirrhosis. In contrast,
CHB patients frequently experience a wide range of fluctuations in
necroinflammatory activity that can result in overestimation of
liver fibrosis but also have macronodular cirrhosis, which can
result in underestimation of liver fibrosis [2,31]. These clinico-
pathological differences have been suggested to explain the
different diagnostic performance and cutoff values of noninvasive
markers such as LSM and FT among studies [9,25,32]. Hence, in
the present study, we focused primarily on Asian patients with
CHB and investigated the accuracy and applicability of ELF test in
comparison with LSM and FT, which are the most popular indices
used currently in clinical practice.
This study has several advantages. First, we prospectively
recruited patients who underwent not only the baseline blood tests
and LSM but also FT and ELF test on the same day as liver
biopsy, and the diagnostic performance of ELF test was compared
to those of LSM and FT, both of which are currently preferred in
France over liver biopsy due to their excellent diagnostic values
[10], and have also been recently validated in Asian populations
with CHB [13,24,33,34]. Furthermore, a relatively large number
of subjects from a single center were consecutively enrolled in this
study, and the distribution of our population was homogeneous
and representative of patients with CHB seen in clinical practice.
Therefore, the optimal cutoff values of ELF test derived from our
study are expected to ultimately be used as reference values for
future studies to elaborate its role in Asian patients with CHB.
Last, we considered only biopsy specimens of 20 mm or larger.
Given that intra- and inter-observer variability may exist in
histological assessment of fibrosis staging, obtaining specimens of
adequate size is of utmost importance to ensure the greatest
possible degree of uniformity [4].
In the present study, the diagnostic performance of ELF test was
comparable to that of the LSM or FT for predicting significant
fibrosis (F$2); AUROC 0.901 vs. 0.937 or 0.896. This is consistent
with several other reports [12,35], suggesting that non-invasive
tests have similar accuracy for detection of significant fibrosis each
other. However, LSM consistently had significantly better
performance than ELF test in predicting both advanced fibrosis
(F$3) (AUROC 0.956 vs. 0.860) and cirrhosis (F = 4) (AUROC
0.963 vs. 0.862). A recent meta-analysis demonstrated a similar
finding, that LSM may be much more accurate for cirrhosis than
for less severe fibrosis stages [16]. Regarding comparison between
ELF test and FT, the diagnostic value of ELF test was significantly
lower than that of FT for diagnosis of advanced fibrosis (F$3)
(0.860 vs. 0.921); however, the performance of the ELF test and
FT for diagnosing significant fibrosis (F$2) (0.901 vs. 0.896) and
cirrhosis (F4) (0.862 vs. 0.881) was actually equivalent (all p.0.05).
In contrast, Friedrich-Rust et al. [19] proposed that ELF test
(AUROC 0.91) can diagnose cirrhosis with comparable diagnostic
accuracy to LSM (AUROC 0.94) and FT (AUROC 0.92).
However, this study was limited in that only a small portion of the
study cohort underwent both LSM and ELF. On the other hand,
another recent study [21] insisted that LSM showed greater
accuracy than ELF for detecting significant fibrosis and cirrhosis.
Taken together, given these controversial results, the performance
of ELF test as a non-invasive alternative compared to LSM or FT
should be further validated.
Table 3. Distribution and agreement of fibrosis stages according to histology and ELF, LSM or FT (n = 170).
Fibrosis stage estimated by ELF
Fibrosis stage estimated by histology F0-1 F2 F3 F4
ELF,8.5 8.5#ELF,9.4 9.4#ELF,10.1 ELF$10.10
F1 41 4 1 3
F2 7 12 9 8
F3 9 5 5 19
F4 0 0 14 33
Fibrosis stage estimated by LSM
Fibrosis stage estimated by histology F0-1 F2 F3 F4
LS,8.0 kPa 8.0#LS,10.1 kPa 10.1#LS,14.0 kPa LS$14.0 kPa
F1 45 3 1 0
F2 20 13 2 1
F3 4 3 18 13
F4 0 1 5 41
Fibrosis stage estimated by FT
Fibrosis stage estimated by histology F0-1 F2 F3 F4
FT,0.31 0.31#FT,0.51 0.51#FT,0.67 FT$0.67
F1 47 2 0 0
F2 21 12 2 1
F3 5 1 14 18
F4 4 2 4 37
Abbreviations: ELF, Enhanced Liver Fibrosis; LSM, liver stiffness measurement; FT, FibroTest.
doi:10.1371/journal.pone.0041964.t003
ELF Test in Asian Chronic Hepatitis B Subjects
PLoS ONE | www.plosone.org 6 July 2012 | Volume 7 | Issue 7 | e41964
Using the Youden method [27], we suggested ELF cutoff values
of 8.5, 9.4, and 10.1 for F$2, F$3, and F= 4, respectively.
However, Parkes et al. [18] reported 10.2 with a maximum sum of
sensitivity (70%) and specificity (85%) for diagnosis of F$3, while
Guecho et al. [36] suggested 9.00, 9.33, and 9.35 for F$2, F$3,
and F= 4, respectively. The suggested thresholds and intervals
between adjacent stages may vary among studies, and they may be
influenced by etiologies, sample size, and the baseline character-
istics of populations. Thus, further external investigations with
larger sample sizes and a balanced fibrosis stage distribution are
needed to validate our data in Asian subjects with CHB.
Regarding discordant results between the histological examina-
tion and ELF test, the presence of histological cirrhosis ultimately
proved to be a single significant factor with a negative association
with the discordant results. Although the lower trend of ALT level
in those with non-discordance compared to those with discordance
seen on univariate analysis (mean value 65 vs. 76 IU/L,
respectively; p=0.035) did not reduce the discordance rate
independently on multivariate analysis, it might be inferred that
this negative correlation between the presence of histological
cirrhosis and discordances can be in part associated with the
different level of ALT in patients with and without histological
cirrhosis (mean value 46 vs. 85 IU/L, respectively; p=0.039), as
observed in several related studies [13,37,38]. Thus, further studies
are required to elucidate the possible confounding variables of
ELF test.
This study did have some limitations. First, as this was a cross-
sectional study, it is not clear whether repeated determination of
ELF score may be useful for tracking the progression of fibrosis
and related clinical outcomes, such as occurrence of hepatic
decompensation and HCC in individual patients. Therefore, the
diagnostic value for prediction of the subsequent development of
cirrhosis and its various complications with sequential ELF tests
during long-term follow-up must be examined further in a
longitudinal study. Second, our population included a small
portion of patients with F0 fibrosis. This could have resulted in a
selection bias and eventually a spectrum bias, since the diagnostic
performance of a given noninvasive test may depend on the
disease prevalence. Since our institute is a tertiary referral hospital
and one of the largest medical centers in South Korea, cases with
advanced disease are likely to be referred for close observation.
When we further analyzed the performance of ELF to distinguish
F$1 from F0, the AUROC was also high (0.904, CI 0.841–0.967)
with an optimal cutoff value of 8.15. However, this result should
be applied in real clinical practice cautiously, considering the small
proportion (only 5.9%) of patients with F0 among entire
population. Taken together, further studies for external validation
based upon a community-based cohort should be performed to
provide more generalized results for patients with CHB. Third, if
we had enrolled more subjects, the diagnostic accuracy of ELF
would have been much better. Indeed, when we added the clinical
data of 36 patients with CHB who were further recruited for
additional 4 months, concordance rate between fibrosis stages
based on histology and ELF had become enhanced up to 61.7%
(vs. 53.5%; Table S2). Thus, a large-scale study should be
followed to provide the solid evidences.
In summary, in a prospective study, we first assessed ELF test in
Asian patients with CHB, demonstrating its considerable diagnos-
tic value for prediction of histological fibrosis stage, and the
optimal suggested cutoff values are expected to be useful in future
studies in those populations. However, LSM consistently provided
better diagnostic values in the higher fibrosis stages. We hope that
other researchers will evaluate the reproducibility of ELF test and
its potential role as a method of classifying liver fibrosis in
independent populations.
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